Brii Biosciences Licenses Rights to BRII-693 in Greater China to Joincare Group
Friday, July 04, 2025
Brii Biosciences Limited (Brii Bio), a biotechnology firm focused on addressing diseases with significant unmet medical needs, has signed a licensing and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd (Joincare Group). Under this agreement, Joincare Group will have exclusive rights to develop and commercialise BRII-693 in the Greater China region.
As part of the deal, Joincare Group will oversee all aspects of development, regulatory approvals, and commercial activities for BRII-693 within the territory. In exchange, Brii Bio has received an upfront payment and is eligible for additional milestone-based payments, along with tiered royalties on future net sales.
BRII-693 is an innovative synthetic lipopeptide designed for the treatment of critically ill patients suffering from multidrug-resistant (MDR) and extensively drug-resistant (XDR) gram-negative bacterial infections. These include infections caused by carbapenem-resistant strains such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacterales. Developed through structural modifications of the polymyxin scaffold, BRII-693 aims to improve antibacterial effectiveness while reducing the kidney and nerve toxicity associated with earlier polymyxin drugs.
In Phase 1 clinical studies, BRII-693 showed a favourable safety and pharmacokinetic profile in both Chinese and non-Chinese healthy volunteers. The drug has received investigational new drug (IND) approval from the Centre for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) to conduct a Phase 1 bridging study, supporting a planned Phase 3 registration trial for hospital-acquired and ventilator-associated bacterial pneumonia.
This partnership combines Brii Bio’s expertise in developing innovative anti-infective therapies with Joincare Group’s established capabilities in antibiotic manufacturing and hospital market distribution. The collaboration is expected to accelerate the availability of BRII-693 in Greater China, offering a new treatment option for patients facing life-threatening bacterial infections.
Brii Bio retains exclusive global rights to BRII-693 outside the Greater China region.
Source: prnewswire.com
